Oculis Holding AG (OCS) Income from Discontinued Operations (2023 - 2024)
Oculis Holding AG's (OCS) quarterly Income from Discontinued Operations came in at 20775.73 in Q3 2024, down 115.82% year-on-year from 131329.7 in Q4 2023, and down 115.82% quarter-over-quarter from 131329.7 in Q3 2023.
Oculis Holding AG (OCS) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Oculis Holding AG's Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 20775.73 for Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -20,775.73 |
| Sep 30, 2023 | 131,329.70 |